Home » Stocks » SYN

Synthetic Biologics, Inc. (SYN)

Stock Price: $0.550 USD -0.030 (-5.19%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 71.31M
Revenue (ttm) n/a
Net Income (ttm) -12.56M
Shares Out 19.01M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $0.550
Previous Close $0.580
Change ($) -0.030
Change (%) -5.19%
Day's Open 0.523
Day's Range 0.460 - 0.580
Day's Volume 17,949,823
52-Week Range 0.252 - 1.700

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 2 months ago

Synthetic Biologics (SYN) stock is soaring higher on heavy trading Tuesday even without a lack of news concerning the company. The post Synthetic Biologics: 6 Things for SYN Stock Investors to...

Seeking Alpha - 3 months ago

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 7 months ago

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript

About SYN

Synthetic Biologics, a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transpla... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2006
CEO
Steven Shallcross
Employees
11
Stock Exchange
NYSEAMERICAN
Ticker Symbol
SYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 1.25, which is an increase of 127.27% from the latest price.

Price Target
$1.25
(127.27% upside)
Analyst Consensus: Buy